Showing 1361-1370 of 3001 results for "".
- Clinical Trial to Compare Stem Cell Treatment to High-Efficacy Biologics for Treatment of Relapsing Multiple Sclerosishttps://practicalneurology.com/news/clinical-trial-to-compare-stem-cell-treatment-to-high-efficacy-biologics-for-treatment-of-relapsing-multiple-sclerosis/2469126/A clinical trial will test autologous hematopoietic stem cell treatment (AHSCT) against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial will compare the safety, efficacy, and cost-effectiveness of the 2 therapeutic approaches and has begun en
- Generic Fingolimod for Relapsing Forms of Multiple Sclerosis Approved by the FDAhttps://practicalneurology.com/news/generic-fingolimod-for-relapsing-forms-of-multiple-sclerosis-approved-by-the-fda/2469094/The Food and Drug Administration (FDA) has approved 3 applications for the first generics of fingolimod (Gilenya; Novartis AG, Basel, Switzerland) for treating relapsing forms of multiple sclerosis (MS) in adult patients. Fingolimod is a sphingosine 1-phosphate receptor modulator indica
- Advancement in Multiple Sclerosis and The Effect on Pregnancyhttps://practicalneurology.com/news/advancement-in-multiple-sclerosis-and-the-effect-on-pregnancy/2469078/On a global level, there is a concerning gap between the results of clinical trials and regulators' approval of advanced therapies, leaving some individuals with multiple sclerosis (MS) without access to the most effective options. Therapeutic lags have resulted in entire regions where indivi
- Partnership Between Community and Academic Healthcare Can Improve Standardization of Imaging Protocols for Multiple Sclerosishttps://practicalneurology.com/news/partnership-between-community-and-academic-healthcare-can-improve-standardization-of-imaging-protocols-for-multiple-sclerosis/2468813/Guidelines exist for standardized MRI for monitoring disease activity in patients with multiple sclerosis (MS) and enhance quality of care for patients as well as creating the opportunity to have standardized data for research. Outside of tertiary care centers, however, these protocols often are
- Rates of Initiating Disease-Modifying Treatment for Multiple Sclerosis Remain Lowhttps://practicalneurology.com/news/rates-of-initiating-disease-modifying-treatment-for-multiple-sclerosis-remain-low/2468819/Research suggests that as many as 43% of patients with multiple sclerosis (MS) do not take a disease-modifying treatment (DMT) for the first 2 years of their diagnosis or longer. In a retrospective claims analysis using the IQVIA adjudicated claims database from June 2010 to June, 2017.
- New Drug Application Novel for Oral Fumarate Accepted by Food and Drug Administrationhttps://practicalneurology.com/news/new-drug-application-novel-for-oral-fumarate-accepted-by-food-and-drug-administration/2468826/The Food and Drug Administration (FDA) has accepted an application for diroximel fumarate (BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for the treatment of relapsing forms of multiple sclerosis (MS). eb. 25, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: B
- Barancik Prize Awarded to Dr. Ruth Ann Marrie at ACTRIMS 2023https://practicalneurology.com/news/barancik-prize-awarded-to-dr-ruth-ann-marrie-at-actrims-2023/2470120/The National Multiple Sclerosis Society announced that Ruth Ann Marrie, MD, P
- Possible Treatment for Focal Laryngeal Dystonia Revealed at MDS Conferencehttps://practicalneurology.com/news/possible-treatment-for-focal-laryngeal-dystonia-reported-at-mds-conference/2470597/Results of a double-blind, placebo-controlled, randomized cross-over study presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders suggest that sodium oxybate (SO) may be an effective treatment for some people with focal laryngeal dystonia (LD). This phase
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Phase 3 Trial of MSC-NTF Stem Cells for ALS Receives Continued Fundinghttps://practicalneurology.com/news/phase-3-trial-of-msc-ntf-stem-cells-for-als-receives-continued-funding/2469289/The ongoing phase 3 clinical trial of autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, Paramus, NJ) treatment has received funding through a grant. The grant was awarded by the ALS Association and